Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Clinical Pharmacology and Therapeutics
|
January 13, 2012
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot
Y Daali, C Samer, J Déglon, et al.
Clinical Pharmacology and Therapeutics
|
April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots
M Bosilkovska, C F Samer, J Déglon, et al.
The Pharmacogenomics Journal
|
July 2, 2008
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction
M C Rebsamen, J Desmeules, Y Daali, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 2, 2022
Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants
Y Gloor, C Lloret-Linares, M Bosilkovska, et al.
Journal of Viral Hepatitis
|
July 6, 2012
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection
F Girardin, Y Daali, M Gex-Fabry, et al.
British Journal of Pharmacology
|
July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
C F Samer, Y Daali, M Wagner, et al.
The Pharmacogenomics Journal
|
October 30, 2013
The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation
C R S Uppugunduri, M A Rezgui, P H Diaz, et al.
British Journal of Pharmacology
|
July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
C F Samer, Y Daali, M Wagner, et al.
Clinical Pharmacology and Therapeutics
|
February 10, 2017
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A S Darwich, K Ogungbenro, A A Vinks, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Clinical Pharmacology and Therapeutics
|
January 13, 2012
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot
Y Daali, C Samer, J Déglon, et al.
Clinical Pharmacology and Therapeutics
|
April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots
M Bosilkovska, C F Samer, J Déglon, et al.
The Pharmacogenomics Journal
|
July 2, 2008
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction
M C Rebsamen, J Desmeules, Y Daali, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 2, 2022
Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants
Y Gloor, C Lloret-Linares, M Bosilkovska, et al.
Journal of Viral Hepatitis
|
July 6, 2012
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection
F Girardin, Y Daali, M Gex-Fabry, et al.
British Journal of Pharmacology
|
July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
C F Samer, Y Daali, M Wagner, et al.
The Pharmacogenomics Journal
|
October 30, 2013
The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation
C R S Uppugunduri, M A Rezgui, P H Diaz, et al.
British Journal of Pharmacology
|
July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
C F Samer, Y Daali, M Wagner, et al.
Clinical Pharmacology and Therapeutics
|
February 10, 2017
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A S Darwich, K Ogungbenro, A A Vinks, et al.
Page
of 3